174422-17-4

Basic information

• Product Name: 2-(4-Methoxyphenyl)-1H-benzimidazole-5-carboxylic acid
• Synonyms: 2-(4-Methoxyphenyl)-1H-benzimidazole-5-carboxylic acid
• CAS NO: 174422-17-4
• Molecular Formula: C₁₅H₁₂N₂O₃
• Molecular Weight: 268.27
• Mol File: 174422-17-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-Methoxyphenyl)-1H-benzimidazole-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Methoxyphenyl)-1H-benzimidazole-5-carboxylic acid(174422-17-4)
• EPA Substance Registry System: 2-(4-Methoxyphenyl)-1H-benzimidazole-5-carboxylic acid(174422-17-4)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 174422-17-4(Hazardous Substances Data)

Usage

General Description

The chemical "2-(4-Methoxyphenyl)-1H-benzimidazole-5-carboxylic acid" is a compound that belongs to the benzimidazole class of chemicals. It consists of a benzimidazole ring with a carboxylic acid group attached at position 5 and a methoxyphenyl group at position 2. This chemical has potential applications in medicinal chemistry, particularly in the development of pharmaceuticals targeting a range of biological processes. It has demonstrated various biological activities, such as anti-cancer, anti-inflammatory, and anti-microbial properties, making it a compound of interest for further research and potential drug development.

Upstream product

• 135-02-4 ortho-anisaldehyde 
• 619-05-6 3,4-diaminobenzoic acid 
• 100-09-4 4-methoxybenzoic acid 
• 36692-49-6 Methyl 3,4-diaminobenzoate 
• 123-11-5 4-methoxy-benzaldehyde 
• 33402-67-4 sodium hydroxy(4-methoxyphenyl)methanesulfonate 
• 1588-83-6 4-amino-3-nitrobenzoic acid 

Downstream Products

• 1259500-80-5 4''-O-(2-(4-methoxyphenyl)-1H-benzimidazole-5-carbonyl)hydrazinecarbonylclarithromycin 
• 747356-47-4 2-(4-Methoxy-phenyl)-1H-benzoimidazole-5-carbonyl chloride 

Relevant articles and documents

Structure-Guided Synthesis and Evaluation of Small-Molecule Inhibitors Targeting Protein–Protein Interactions of BRCA1 tBRCT Domain

The tandem BRCT domains (tBRCT) of BRCA1 engage phosphoserine-containing motifs in target proteins to propagate intracellular signals initiated by DNA damage, thereby controlling cell cycle arrest and DNA repair. Recently, we identified Bractoppin, the fi

NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR

Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives

Novel 4″-O-benzimidazolyl clarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activities. These benzimidazolyl derivatives exhibited excellent activity against erythromycin-susceptible strains better than the references, and some of them showed greatly improved activity against erythromycin-resistant strains. Compounds 16 and 17, which have the terminal 2-(4-methylphenyl)benzimidazolyl and 2-(2-methoxyphenyl)benzimidazolyl groups on the C-4″ bishydrazide side chains, were the most active against erythromycin-resistant Staphylococcus pneumoniae expressing the erm gene and the mef gene. In addition, compound 17 exhibited the highest activity against erythromycin-susceptible S. pneumoniae ATCC49619 and Staphylococcus aureus ATCC25923 as well. It is worth noting that the 4″-O-(2-aryl)benzimidazolyl derivatives show higher activity against erythromycin-susceptible and erythromycin-resistant strains than the 4″-O-(2-alkyl)benzimidazolyl derivatives.